Transcept seeks regulatory approval for Intermezzo

POINT RICHMOND, Calif. — Transcept Pharmaceuticals has resubmitted its regulatory application for a drug to treat insomnia to the Food and Drug Administration, following a previous denial of approval by the agency, the drug maker said Tuesday.

Transcept sent in its application for Intermezzo (zolpidem tartrate), a pill placed under the tongue for treating patients who awake in the middle of the night and have difficulty falling asleep again.

In October 2009, the company received a complete response letter from the FDA, and the resubmission contains additional clinical study data.

Login or Register to post a comment.